The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 3, 2007, Pages 228-235

  Gonzalgo, Mark L ^a   Datar, Ram H ^b   Schoenberg, Mark P ^a   Cote, Richard J ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bladder cancer; Diagnosis; DNA methylation; Prognosis

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P16; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UVOMORULIN;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CHROMOSOMAL INSTABILITY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SILENCER ELEMENT;

DNA METHYLATION; HUMANS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 34247610519     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.07.020     Document Type: Article

References (66)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer. J Clin 56 (2006) 106-130
2. Skinner D.G., and Lieskovsky G.L. Management of invasive and high-grade bladder cancer. In: Skinner D.G., and Lieskovsky G.L. (Eds). Diagnosis and management of genitourinary cancer (1988), Saunders, Philadelphia,(PA) 295-312
3. Stonehill W.H., Dmochowski R.R., Patterson A.L., et al. Risk factors for bladder tumors in spinal cord injury patients. J Urol 55 (1996) 1248-1250
4. Spruck C.H., Ohnseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional carcinoma of the bladder. Cancer Res 54 (1994) 784-788
5. Cairns P., Shaw M.E., and Knowles M.A. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res 53 (1993) 1230-1232
6. Simoneau A.R., Spruck C.H., and Gonzalez-Zulueta M. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 56 (1996) 5039-5043
7. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (2002) 415-428
8. Gonzalgo M.L., and Jones P.A. Mutagenic and epigenetic effects of DNA methylation. Mutat Res 386 (1997) 107-118
9. Jones P.A., and Gonzalgo M.L. Altered DNA methylation and genome instability: A new pathway to cancer?. Proc Natl Acad Sci U S A 94 (1997) 2103-2105
10. Li E., Bestor T.H., and Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69 (1992) 915-926
11. Coulondre C., Miller J.H., Farabaugh P.J., et al. Molecular basis of base substitution hotspots in Escherichia coli. Nature 274 (1978) 775-780
12. Cooper D.N., and Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet 78 (1988) 151-155
13. Sved J., and Bird A. The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. Proc Natl Acad Sci U S A 87 (1990) 4692-4696
14. Magewu A.N., and Jones P.A. Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. Mol Cell Biol 14 (1994) 4225-4232
15. Smith N.D., Rubenstein J.N., Eggener S.E., et al. The p53 tumor suppressor gene and nuclear protein: Basic science review and relevance in the management of bladder cancer. J Urol 169 (2003) 1219-1228
16. Greenblatt M.S., Bennett W.P., Hollstein M., et al. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54 (1994) 4855-4878
17. Rideout III W.M., Coetzee G.A., Olumi A.F., et al. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249 (1990) 1288-1290
18. Tornaletti S., and Pfeifer G.P. Complete and tissue-independent methylation of CpG sites in the p53 gene: Implications for mutations in human cancers. Oncogene 10 (1995) 1493-1499
19. Markl I.D., and Jones P.A. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 58 (1998) 5348-5353
20. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
21. Jones P.A., Gonzalgo M.L., Tsutsumi M., et al. DNA methylation in bladder cancer. Eur Urol 33 (1998) 7-8
22. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 321 (1986) 209-213
23. Cedar H. DNA methylation and gene activity. Cell 53 (1988) 3-4
24. Bird A.P., and Wolffe A.P. Methylation-induced repression-belts, braces, and chromatin. Cell 99 (1999) 451-454
25. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 (1993) 704-707
26. Spruck C.H., Gonzalez-Zulueta M., Shibata A., et al. p16 gene in uncultured tumors. Nature 370 (1994) 183-184
27. Herman J.G., Merlo A., Mao L., et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55 (1995) 4525-4530
28. Gonzalez-Zulueta M., Bender C.M., Yang A.S., et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55 (1995) 4531-4535
29. Maruyama R., Toyooka S., Toyooka K.O., et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61 (2001) 8659-8663
30. Chan M.W., Chan L.W., Tang N.L., et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8 (2002) 464-470
31. Tada Y., Wada M., Kuroiwa K., et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 6 (2000) 4618-4627
32. Habuchi T., Takahashi T., Kakinuma H., et al. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 20 (2001) 531-537
33. Bornman D.M., Mathew S., Alsruhe J., et al. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol 159 (2001) 831-835
34. Ribeiro-Filho L.A., Franks J., Sasaki M., et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 34 (2002) 187-198
35. Pao M.M., Tsutsumi M., Liang G., et al. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 10 (2001) 903-910
36. Salem C.E., Markl I.D., Bender C.M., et al. PAX6 methylation and ectopic expression in human tumor cells. Int J Cancer 87 (2000) 179-185
37. Lee M.G., Kim H.Y., Byun D.S., et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 61 (2001) 6688-6692
38. Dhawan D., Hamdy F.C., Rehman I., et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Path 209 (2006) 336-343
39. Chang L.L., Yeh W.T., Yang S.Y., et al. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 170 (2003) 595-600
40. Dominguez G., Carballido J., Silva J., et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 8 (2002) 980-985
41. Muto S., Horie S., Takahashi S., et al. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 60 (2000) 4021-4025
42. Gonzalgo M.L., Hayashida T., Bender C.M., et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 58 (1998) 1245-1252
43. Graff J.R., Herman J.G., Lapidus R.G., et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55 (1995) 5195-5199
44. Horikawa Y., Sugano K., Shigyo M., et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol 169 (2003) 1541-1545
45. Ahuja N., and Issa J.P. Aging, methylation and cancer. Histol Histopathol 15 (2000) 835-842
46. Maruyama R., Toyooka S., Toyooka K.O., et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8 (2002) 514-519
47. Thievessen I., Seifert H.H., Swiatkowski S., et al. E-cadherin involved in inactivation of WNT/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer 88 (2003) 1932-1938
48. Dammann R., Li C., Yoon J.H., et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25 (2000) 315-319
49. Dammann R., Yang G., and Pfeifer G.P. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 61 (2001) 3105-3109
50. Baylin S.B., Esteller M., Rountree M.R., et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10 (2001) 687-692
51. Velicescu M., Weisenberger D.J., Gonzales F.A., et al. Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res 62 (2002) 2378-2384
52. Jurgens B., Schmitz-Drager B.J., and Schulz W.A. Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res 56 (1996) 5698-5703
53. Kimura F., Seifert H.H., Florl A.R., et al. Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma. Int J Cancer 104 (2003) 568-578
54. Gonzalgo M.L., and Jones P.A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res 25 (1997) 2529-2531
55. Liang G., Salem C.E., Yu M.C., et al. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 53 (1998) 260-268
56. Markl I.D., Cheng J., Liang G., et al. Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res 61 (2001) 5875-5884
57. Liang G., Gonzales F.A., Jones P.A., et al. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 62 (2002) 961-966
58. Xiong Z., and Laird P.W. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25 (1997) 2532-2534
59. Trinh B.N., Long T.I., and Laird P.W. DNA methylation analysis by MethyLight technology. Methods 25 (2001) 456-462
60. Adorjan P., Distler J., Lipscher E., et al. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res 30 (2002) e21
61. Goessl C., Muller M., Straub B., et al. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 41 (2002) 668-676
62. Valenzuela M.T., Galisteo R., Zuluaga A., et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol 42 (2002) 622-628
63. Tada Y., Wada M., Taguchi K., et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62 (2002) 4048-4053
64. Bender C.M., Pao M.M., and Jones P.A. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58 (1998) 95-101
65. Cheng J.C., Matsen C.B., Gonzales F.A., et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95 (2003) 399-409
66. Yang S.A., Doshi K.D., Choi S.-W., et al. DNA methylation changes after 5-Aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66 (2006) 5495-5503